| Identification | Back Directory | [Name]
5-(4-(2-(3-METHOXYPHENYL)-2-OXOETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE | [CAS]
1133819-87-0 | [Synonyms]
MSDC 0602
Azemiglitazone
MSDC-0602; MSDC0602; MSDC 0602
5-(4-(2-(3-METHOXYPHENYL)-2-OXOETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE
5-[[4-[2-(3-Methoxyphenyl)-2-oxoethoxy]phenyl]methyl]-2,4-thiazolidinedione
2,4-Thiazolidinedione, 5-[[4-[2-(3-methoxyphenyl)-2-oxoethoxy]phenyl]methyl]- | [Molecular Formula]
C19H17NO5S | [MDL Number]
MFCD28502493 | [MOL File]
1133819-87-0.mol | [Molecular Weight]
371.41 |
| Chemical Properties | Back Directory | [Melting point ]
>176°C (dec.) | [storage temp. ]
Hygroscopic, -20°C Freezer, Under inert atmosphere | [solubility ]
DMSO (Slightly), Methanol (Slightly, Heated) | [form ]
Solid | [color ]
Pale Yellow to Light Yellow |
| Hazard Information | Back Directory | [Uses]
MSDC 0602, an analogue of?thiazolidinediones, exhibits low affinity for binding and activation of peroxisome proliferator-activated receptor γ (PPARγ). Thiazolidinediones are effective insulin-sensitizing drugs for treating various metabolic and inflammatory diseases. | [in vivo]
Azemiglitazone (2-5 μM in blood, p.o for 2-4 weeks) improves insulin sensitivity in striated muscle, adipose tissue, and liver of DIO C57BL/6 mice[6].
Azemiglitazone (2-5 μM in blood, p.o for 2-4 weeks) improves mitochondrial respiratory rate in DIO C57BL/6 mice[6].
Azemiglitazone reduces NASH caused liver injury, prevents (2-5 μM in blood, p.o. for 12 weeks) and reverses (2-5 μM in blood, p.o. for 3 weeks) stellate cells activation and fibrosis in HTF-C diet feeding C57BL6/J mice[4].
Azemiglitazone (2-5 μM in blood, p.o.) causes weight loss and suppresses stellate cell activation with or without MPC function in HTF-C diet feeding LS-Mpc2-/-C57BL6/J mice[4].
| Animal Model: | HTF-C diet feeding C57BL6/J mice [4] | | Dosage: | 331 ppm MSDC-0602 potassium salt (2-5 μM Azemiglitazone in blood) | | Administration: | oral administration for 12 weeks (after 4 weeks of HTF-C diet) or 3 weeks (16 weeks after HTF-C diet) | | Result: | Induced weight loss, decreased concentrations of plasma ALT and AST and stellate cell activation. |
| Animal Model: | HTF-C diet feeding LS-Mpc2-/-C57BL6/J mice [4] | | Dosage: | 331 ppm MSDC-0602 potassium salt (2-5 μM Azemiglitazone in blood) | | Administration: | oral administration for 12 weeks (after 4 weeks of HTF-C diet) | | Result: | Induced weight loss, suppressed stellate cell activation. |
| Animal Model: | diet induced obesity C57BL/6 mice[6] | | Dosage: | 300 ppm MSDC-0602 (2-5 μM Azemiglitazone in blood) | | Administration: | oral administration for 2-4 weeks | | Result: | Reduced insulin concentration in plasma, increased glucose infusion rate and glucose uptake into gastrocnemius, adipose tissue, and heart.
Improved mitochondrial oxygen consumption. |
|
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|